Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus rituximab with dose-dense ACVBP14 or CHOP14 in untreated high-risk DLBCL using a PET-driven strategy
2011-005851-15Phase 3Completed
- Sponsor
- LYSARC
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of obinutuzumab and rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by LYSARC. Primary endpoint: Event-free survival. Started Oct 2012; status: completed.
02
Drugs
obinutuzumabrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-005851-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005851-15.